Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease.
Hollenback D, Hambruch E, Fink G, Birkel M, Schulz A, Hornberger M, Liu K, Staiger KM, Krol HD, Deuschle U, Steeneck C, Kinzel O, Liles JT, Budas G, Watkins WJ, Kremoser C.
Hollenback D, et al. Among authors: birkel m.
J Pharmacol Exp Ther. 2024 Mar 15;389(1):61-75. doi: 10.1124/jpet.123.001900.
J Pharmacol Exp Ther. 2024.
PMID: 38409114